Related Experiment Video
Updated: Jun 4, 2025
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Pharmacotherapeutic options for coronary thrombosis treatment: where are we today?
Mohammed Ejaz Faizur Rahman1,2, Vidun Wedagedera1, William A E Parker1,2
1Cardiovascular Research Unit, Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK.
Insights
Optimizing antithrombotic therapy for coronary thrombosis requires understanding drug mechanisms and pathophysiology. This review guides clinicians in individualizing treatment for better outcomes in coronary artery disease patients.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis Research
Background:
- Pharmacotherapy for coronary thrombosis has advanced, improving patient outcomes but increasing treatment complexity.
- Percutaneous coronary intervention and stent design have reduced thrombotic complications, posing challenges for clinical trials.
- Understanding coronary thrombosis pathophysiology and antithrombotic drug mechanisms is crucial for effective therapeutic decisions.
Purpose of the Study:
- To review the pathophysiology of coronary thrombosis and mechanisms of action of relevant drugs.
- To provide an overview of decision-making issues in antithrombotic therapy.
- To guide clinicians in individualizing risk management and address evidence gaps.
Main Methods:
- Literature review of coronary thrombosis pathophysiology.
- Analysis of antithrombotic drug mechanisms and clinical trial data.
- Critical appraisal of current pharmacotherapy strategies and evidence.
Main Results:
- Individualization of antithrombotic therapy is key for optimizing risk management.
- Strengths and limitations of available antithrombotic drugs and combinations are appraised.
- Gaps in the evidence base for pharmacotherapy are identified.
Conclusions:
- Clinicians need to understand drug characteristics and pathophysiology for informed decisions.
- Individualized antithrombotic regimens are vital for managing coronary thrombosis.
- Further research is needed to improve pharmacotherapy for coronary thrombosis treatment and prevention.
Introduction:
Advances in pharmacotherapy for coronary thrombosis treatment and prevention have transformed the clinical outcomes of patients with coronary artery disease but increased the complexity of therapeutic decision-making. Improvements in percutaneous coronary intervention techniques and stent design have reduced the incidence of thrombotic complications, which consequently has increased the challenge of adequately powering clinical trials of novel antithrombotic strategies for efficacy outcomes. Knowledge of the pathophysiology of coronary thrombosis and the characteristics of antithrombotic drugs can help with therapeutic decisions.
Areas Covered:
This review covers the pathophysiology of coronary thrombosis and the mechanisms of action of drugs developed for its treatment, provides an overview of the key issues in decision-making, and highlights key areas for further work in order to guide clinicians on how to individualize risk management and address gaps in the evidence base.
Expert Opinion:
Individualization of antithrombotic therapy regimens has become a vital part of optimizing risk management in people with coronary thrombosis. A critical appraisal of the strengths and limitations of available drugs and the evidence supporting the use of different antithrombotic combinations is intended to provide direction to clinicians and point the way toward further improvements in pharmacotherapy for coronary thrombosis treatment and prevention.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins